Department of Allergy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology (HUST), Wuhan, 430030, Hubei, China.
Ital J Pediatr. 2021 Apr 23;47(1):101. doi: 10.1186/s13052-021-01046-z.
Allergen immunotherapy (AIT) is the only causal therapy for IgE-mediated allergy. There is less evidence about the safety and efficacy of AIT especially subcutaneous immunotherapy (SCIT) in children under 5 years old. We aimed to investigate the side effects and associated risk factors of house dust mite (HDM) SCIT in preschool children with respiratory allergic diseases.
The preschool children who had HDM-related allergic rhinitis with/without asthma were enrolled and undergone standardized HDM SCIT in our department from June 2013 to December 2019. Local reactions (LRs) and systemic reactions (SRs) were recorded and categorized according to World Allergy Organization recommendations. Demographic data and other therapeutic-related parameters were also recorded to investigate potential risk factors for these side effects.
A total of 91 children (60 boys, 65.93%; 31 girls, 34.07%; mean age 4.13 years old) were included in the study. Among the 91 patients, 3109 SCIT injections were recorded, 62/91 (68.13%) experienced 186 immediate LRs, 4 /91(4.40%) experienced 6 delayed LRs, 11/91 (12.09%) children experienced 44 immediate SRs, 21/44 (47.73%) were grade 1 SRs, 21/44 (47.73%) were grade 2, 2/44 (4.55%) were grade 3, no grade 4 or 5 SRs occurred. Furthermore, 1/91 (1.10%) experienced 1 delayed SRs, manifested by urticaria 2 days later after allergen injection. 9/91 (9.89%) experienced 2 or more times SRs. Multivariable logistic regression analysis showed BMI (OR 1.506; 95%CI 1.091 to 2.079; p < 0.05) and sIgE against HDM (OR 1.497; 95%CI 1.082 to 2.071; p < 0.05) were risk factors for LRs. No variable was found to correlate with SRs (all p > 0.05).
HDM subcutaneous immunotherapy is considered to be safe in preschool children with respiratory allergic diseases. Higher BMI and HDM sIgE level in children are risk factors for developing LRs. The incidence of SRs and the rate of severe SRs are low in preschool children.
变应原免疫疗法(AIT)是 IgE 介导过敏的唯一因果疗法。对于 5 岁以下儿童,皮下免疫疗法(SCIT)的安全性和疗效证据较少。我们旨在研究尘螨(HDM)SCIT 在患有呼吸道过敏性疾病的学龄前儿童中的副作用和相关危险因素。
2013 年 6 月至 2019 年 12 月,本部门收治了患有 HDM 相关变应性鼻炎伴/不伴哮喘的学龄前儿童,并对其进行了标准化的 HDM SCIT。根据世界过敏组织的建议,记录局部反应(LR)和全身反应(SR)并进行分类。还记录了人口统计学数据和其他治疗相关参数,以调查这些副作用的潜在危险因素。
共纳入 91 例患儿(男 60 例,65.93%;女 31 例,34.07%;平均年龄 4.13 岁)。91 例患者中,共记录了 3109 次 SCIT 注射,62/91(68.13%)例发生 186 次即刻 LR,4/91(4.40%)例发生 6 次延迟 LR,11/91(12.09%)例发生 44 次即刻 SR,21/44(47.73%)例为 1 级 SR,21/44(47.73%)例为 2 级,2/44(4.55%)例为 3 级,无 4 级或 5 级 SR。此外,1/91(1.10%)例发生 1 次延迟性 SR,表现为过敏原注射后 2 天出现荨麻疹。91 例中有 9 例(9.89%)发生 2 次或以上 SR。多变量逻辑回归分析显示 BMI(比值比 1.506;95%可信区间 1.091 至 2.079;p<0.05)和 HDM 特异性 IgE(比值比 1.497;95%可信区间 1.082 至 2.071;p<0.05)是 LR 的危险因素。没有变量与 SR 相关(p 均>0.05)。
HDM 皮下免疫疗法在患有呼吸道过敏性疾病的学龄前儿童中被认为是安全的。儿童较高的 BMI 和 HDM 特异性 IgE 水平是发生 LR 的危险因素。在学龄前儿童中,SR 的发生率和严重 SR 的发生率较低。